48 results about "Silicon phthalocyanine" patented technology

An electrostatic latent image developing toner comprising at least a resin, a wax and a colorant, wherein the wax comprises 40 to 98% by mass of a first release agent comprising an ester wax and 2 to 60% by mass of a second release agent comprising a hydrocarbon having at least one of a branched chain structure and a cyclic structure; and the colorant comprises a silicon phthalocyanine represented by Formula (I):

The present invention relates to a method for preparing a silica particle including at least one phthalocyanine derivative, said particle being prepared from at least one silicon phthalocyanine derivative via reverse microemulsion, to said silica particles, and to the uses thereof.

The invention discloses silicon phthalocyanine axially modified by aminoethyl phenoxyl and polyethylene glycol oligomer as well as a preparation method and application of silicon phthalocyanine, belonging to the field of preparation of photodynamic medicaments or photosensitizers. The silicon phthalocyanine provided by the invention can be used as a photosensitizer for photodynamic treatment, photodynamic diagnosis or photodynamic sterilization, has the structural characteristic of axially asymmetrical substitution and shows favorable amphipathy and extremely high photodynamic activity.

Systems and methods for aromatic macrocyclic compounds (Phthalocyanines) as cathode additives for inhibition of transition metal dissolution and stable solid electrolyte interphase formation may include an anode, an electrolyte, and a cathode, where the cathode comprises an active material and a phthalocyanine additive, the additive being coordinated with different metal cationic center and functional groups. The active material may comprise one or more of: nickel cobalt aluminum oxide, nickel cobalt manganese oxide, lithium iron phosphate, lithium cobalt oxide, and lithium manganese oxide, Ni-rich layered oxides LiNi1−xMxO2 where M=Co, Mn, or Al, Li-rich xLi2MnO3(1−x)LiNiaCobMncO2, Li-rich layered oxides LiNi1+xM1−O2 where M=Co, Mn, or Ni, and spinel oxides LiNi0.5Mn1.5O4. The phthalocyanine additive may include one or more of: cobalt hexadecafluoro phthalocyanine (Co-Pc-F), dilithium phthalocyanine (Li-Pc), cobalt(II) phthalocyanine, nickel(II) phthalocyanine-tetrasulfonic acid tetrasodium salt, titanium(IV) phthalocyanine dichloride, manganese(II) phthalocyanine, zinc phthalocyanine, aluminum phthalocyanine chloride, Iron(II) phthalocyanine, and silicon phthalocyanine dichloride.

The invention discloses a silicon phthalocyanine axially bonded with a piperidine or morpholine derivative with an ester bond as well as a preparation method and application of the silicon phthalocyanine and belongs to the field of preparing photodynamic drugs or photosensitizers. The silicon phthalocyanine can be used as a photosensitizer used for carrying out photodynamic antibacterium, photodynamic cancer resistance, photodynamically treating other diseases, photodynamic disinfection and photodynamic diagnosis and has the advantages of simple preparation, strong photosensitization and the like, and the maximum absorption spectrum is located in a near infrared region.

The invention discloses a silicon phthalocyanine asymmetrically modified by axial nucleosides, a preparation method and application thereof, and belongs to the field of preparation of photodynamic drugs or photosensitizers. The axial nucleoside asymmetrically modified silicon phthalocyanine provided by the present invention can be used as a photosensitizer for photodynamic therapy, photodynamic diagnosis or photodynamic disinfection. It has the structural characteristics of axial asymmetric substitution and shows good amphiphile and high photodynamic activity.

The invention discloses an axially substitutive silicon phthalocyanine complex and a doxorubicin conjugate thereof and a preparation method and application of the axially substitutive silicon phthalocyanine complex and the doxorubicin conjugate thereof, and belongs to the technical field of photosensitizer and drug preparation.The complex can be prepared into a novel efficient photodynamic drug or photosensitizer, and the complex and doxorubicin can be prepared into the silicon phthalocyanine-doxorubicin conjugate.The coupling agent has both a photodynamic therapy effect and a chemotherapy effect and can be prepared into a novel anti-cancer drug.